[
  {
    "ts": null,
    "headline": "Regeneron announces initial results from two cohorts of LINKER-MM2 trial",
    "summary": "Regeneron (REGN) announced initial results from two cohorts of the Phase 1b LINKER-MM2 trial evaluating linvoseltamab in combination with two different proteasome inhibitors – carfilzomib or bortezomib – in patients with relapsed/refractory multiple myeloma. The trial included patients who had progressed after at least two lines of therapy and were either double-class refractory or triple-class exposed. The data will be featured in two oral presentations at the American Society of Clinical Oncol",
    "url": "https://finnhub.io/api/news?id=74b336632eaebad4665ceaff3a403040364b71ab000a2e95546e270ff6c77576",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748034613,
      "headline": "Regeneron announces initial results from two cohorts of LINKER-MM2 trial",
      "id": 134685928,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron (REGN) announced initial results from two cohorts of the Phase 1b LINKER-MM2 trial evaluating linvoseltamab in combination with two different proteasome inhibitors – carfilzomib or bortezomib – in patients with relapsed/refractory multiple myeloma. The trial included patients who had progressed after at least two lines of therapy and were either double-class refractory or triple-class exposed. The data will be featured in two oral presentations at the American Society of Clinical Oncol",
      "url": "https://finnhub.io/api/news?id=74b336632eaebad4665ceaff3a403040364b71ab000a2e95546e270ff6c77576"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Initial Data on Multiple Myeloma Drug Encouraging",
    "summary": "REGN posts strong early data for linvoseltamab combos in relapsed/refractory multiple myeloma, with ORRs up to 90% and high complete response rates.",
    "url": "https://finnhub.io/api/news?id=c100da9a9f318f0fe357f2990454f9f91351a60eeb5ce3fe20dbc57b9871f6a2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748030940,
      "headline": "Regeneron Initial Data on Multiple Myeloma Drug Encouraging",
      "id": 134685929,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "REGN posts strong early data for linvoseltamab combos in relapsed/refractory multiple myeloma, with ORRs up to 90% and high complete response rates.",
      "url": "https://finnhub.io/api/news?id=c100da9a9f318f0fe357f2990454f9f91351a60eeb5ce3fe20dbc57b9871f6a2"
    }
  },
  {
    "ts": null,
    "headline": "Roche Gets FDA Nod for Label Expansion of Susvimo for Third Indication",
    "summary": "FDA approves RHHBY's Susvimo for diabetic retinopathy, its third indication, offering 9-month relief with one treatment.",
    "url": "https://finnhub.io/api/news?id=de597e0e5618655dc2f7e202a71d92176b70bb63b59b74ed97301dd74e77f4c0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748030520,
      "headline": "Roche Gets FDA Nod for Label Expansion of Susvimo for Third Indication",
      "id": 134685841,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "FDA approves RHHBY's Susvimo for diabetic retinopathy, its third indication, offering 9-month relief with one treatment.",
      "url": "https://finnhub.io/api/news?id=de597e0e5618655dc2f7e202a71d92176b70bb63b59b74ed97301dd74e77f4c0"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals (NasdaqGS:REGN) Reports Promising Results In LINKER-MM2 Trial For Linvoseltamab",
    "summary": "Regeneron Pharmaceuticals (NasdaqGS:REGN) experienced a 2% increase in its share price over the past week as the company announced promising initial results from the Phase 1b LINKER-MM2 trial related to linvoseltamab for treating relapsed/refractory multiple myeloma. These results, which detailed robust efficacy rates and plans for further trials, came at a time when many major indices were experiencing declines due to renewed trade tension concerns. Thus, Regeneron's positive clinical trial...",
    "url": "https://finnhub.io/api/news?id=f929b027fa7d369721baa0744db5d2bfb68064924409a3c8aac4ea2bb9c16326",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748021176,
      "headline": "Regeneron Pharmaceuticals (NasdaqGS:REGN) Reports Promising Results In LINKER-MM2 Trial For Linvoseltamab",
      "id": 134685932,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron Pharmaceuticals (NasdaqGS:REGN) experienced a 2% increase in its share price over the past week as the company announced promising initial results from the Phase 1b LINKER-MM2 trial related to linvoseltamab for treating relapsed/refractory multiple myeloma. These results, which detailed robust efficacy rates and plans for further trials, came at a time when many major indices were experiencing declines due to renewed trade tension concerns. Thus, Regeneron's positive clinical trial...",
      "url": "https://finnhub.io/api/news?id=f929b027fa7d369721baa0744db5d2bfb68064924409a3c8aac4ea2bb9c16326"
    }
  },
  {
    "ts": null,
    "headline": "Vertex: Continuing To Dominate In CF, But What About Its Pain Pipeline?",
    "summary": "Vertex Pharmaceuticals has solid revenue projections for its CF franchise, and a promising drug pipeline, especially in pain. Click to read why VRTX is a Buy.",
    "url": "https://finnhub.io/api/news?id=6723b8b091a6b77518608ce5f37e5c1eb72d9fc217c1ae3d6a56933a9ad8073b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747993615,
      "headline": "Vertex: Continuing To Dominate In CF, But What About Its Pain Pipeline?",
      "id": 134660926,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2174377045/image_2174377045.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "Vertex Pharmaceuticals has solid revenue projections for its CF franchise, and a promising drug pipeline, especially in pain. Click to read why VRTX is a Buy.",
      "url": "https://finnhub.io/api/news?id=6723b8b091a6b77518608ce5f37e5c1eb72d9fc217c1ae3d6a56933a9ad8073b"
    }
  },
  {
    "ts": null,
    "headline": "Strokes and Heart Attacks Kill. New Drugs Are Coming to Prevent Them.",
    "summary": "Successful trial results in the next few years could save thousands of lives and generate billions in new annual revenue for drugmakers.",
    "url": "https://finnhub.io/api/news?id=8062ff2e781ade5612d612e1985dfd5895dc3b8c85ea04606e84437d016705bb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747983600,
      "headline": "Strokes and Heart Attacks Kill. New Drugs Are Coming to Prevent Them.",
      "id": 134658385,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Successful trial results in the next few years could save thousands of lives and generate billions in new annual revenue for drugmakers.",
      "url": "https://finnhub.io/api/news?id=8062ff2e781ade5612d612e1985dfd5895dc3b8c85ea04606e84437d016705bb"
    }
  }
]